Adrenomedullin
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Adrenomedullin
| ||||||||||||||
| Identifiers | ||||||||||||||
| Symbol(s) | ADM; AM | |||||||||||||
| External IDs | OMIM: 103275 MGI: 108058 Homologene: 873 | |||||||||||||
| ||||||||||||||
| RNA expression pattern | ||||||||||||||
| Orthologs | ||||||||||||||
| Human | Mouse | |||||||||||||
| Entrez | 133 | 11535 | ||||||||||||
| Ensembl | ENSG00000148926 | ENSMUSG00000030790 | ||||||||||||
| Uniprot | P35318 | Q6GTK2 | ||||||||||||
| Refseq | NM_001124 (mRNA) NP_001115 (protein) | NM_009627 (mRNA) NP_033757 (protein) | ||||||||||||
| Location | Chr 11: 10.28 - 10.29 Mb | Chr 7: 110.42 - 110.42 Mb | ||||||||||||
| Pubmed search | [1] | [2] | ||||||||||||
|
WikiDoc Resources for Adrenomedullin | |
|
Articles | |
|---|---|
|
Most recent articles on Adrenomedullin Most cited articles on Adrenomedullin | |
|
Media | |
|
Powerpoint slides on Adrenomedullin | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Adrenomedullin at Clinical Trials.gov Trial results on Adrenomedullin Clinical Trials on Adrenomedullin at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Adrenomedullin NICE Guidance on Adrenomedullin
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Adrenomedullin Discussion groups on Adrenomedullin Patient Handouts on Adrenomedullin Directions to Hospitals Treating Adrenomedullin Risk calculators and risk factors for Adrenomedullin
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Adrenomedullin | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [3] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Adrenomedullin is a peptide associated with pheochromocytoma. It was discovered in 1993.[1]
Adrenomedullin (AM) is a ubiquitously expressed peptide initially isolated from phaechromyctoma in 1993 (Kitamura et al., 1998). Since its first report, studies examining the effects of adrenomedullin have mushroomed, highlighting its role in a number of diseases. Recently a second peptide AM2 has been recognised, exhibiting similar functions (Fujisawa et al., 2004).
The Adrenomedullin Peptide
The human AM gene is localized to a single locus on Chromosome 11 with 4 exons and 3 introns. The AM gene initially codes for a 185-amino acid precursor peptide [3], that can be differentially excised to form a number of peptides, including an inactive 53-amino acid AM, e PAMP, adrenotensin and AM95-146. Mature human AM is activated to form a 52 amino acid, 6-amino acid ring, that shares moderate structural similarity to the calcitonin family of regulatory peptides (calcitonin, CGRP and amylin). Circulating AM consists of both amidated (mature) and the glycated form (inactive, with the latter comprising the major form (85%) [5]. The measured to have a plasma half-life of 22min, mean clearance rate of 274 mL/kg/min, and apparent volume of distribution of 880+/- 150 mL/kg (Meeran et al., 1997). Mature AM is metabolised via aminopeptidase action.
Receptors of Adrenomedullin
At present AM is believed to function through through the combination of a few combinations of the calitonin receptor like receptor (CL) and receptor activity-modifying proteins (RAMP) complexes, as well as CGRP receptors. It is worth noting that unlike the classical one ligand-one receptor notion of receptor signalling, the interaction of both CL and RAMP at the membrane, is required for AM to mediate its action. The outcome of AM stimulatation of its receptor is the cellular production of both cyclic AMP (cAMP) and nitric oxide production. Some may find the production of these inside the cell to be at odds, since often they have opposing effects, but as yet, the timing of these effects remains to be studied.
The physiological functions of Adrenomedullin
AM was initially identified as a vasodilator, some have cited this as the most potent endogenous vasodilatory peptide found in the body (Cockcroft et al., 1997). Differences in opinion regarding the ability of AM to relax vascular tone arises from the differences in the model system used (Hamid and Baxter, 2005). Other effects of AM include increasing the tolerance of cells to oxidative stress and hypoxic injury and angiogenesis. AM is seen as a positive influence in diseases such as hypertension, myocardial infarction, chronic obstructive pulmonary disease and other cardiovascular diseases, whereas it can be seen as a negative factor in potentiating the potential of cancerous cells to extend their blood supply and cause cell proliferation.
References
Further reading
- Cao et al., Regulated Peptide, 113(1-3),109-114. 2003.
- Cockcroft et al., Br J Clin Pharmacol. 1997 Jul;44(1):57-60.
- Fujisawa Y et al., Eur J Pharmacol. Aug 16;497(1):75-80. 2004.
- Hamid SA, Baxter GF, Pharmacol Ther. Feb;105(2):95-112.2005.
- Kitamura et al., Biochem Biophys Res Commum, 244(2), 551-555. 1998.
- Meeran K et al., J Clin Endocrinol Metab. Jan;82(1):95-100. 1997
External links
 | This protein-related article is a stub. You can help WikiDoc by expanding it. |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
